FDA Approved: ENJAYMO — Supplemental Application (Recordati Rare Diseases, Inc.)

View source ↗

Summary

The FDA approved a supplemental application for ENJAYMO (sutimlimab-jome) submitted by Recordati Rare Diseases, Inc.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cold Agglutinin Disease

Drugs mentioned

• Enjaymo (sutimlimab)

Snippet

SUPPL AP for ENJAYMO (SUTIMLIMAB-JOME)